John L. Higgins
2020
In 2020, John L. Higgins earned a total compensation of $5.8M as Chief Executive Officer at Ligand Pharmaceuticals, a 14% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $501,250 |
|---|---|
| Option Awards | $2,389,544 |
| Salary | $668,333 |
| Stock Awards | $2,277,460 |
| Other | $6,180 |
| Total | $5,842,767 |
Higgins received $2.4M in option awards, accounting for 41% of the total pay in 2020.
Higgins also received $501.3K in non-equity incentive plan, $668.3K in salary, $2.3M in stock awards and $6.2K in other compensation.
Rankings
In 2020, John L. Higgins' compensation ranked 1,813th out of 13,090 executives tracked by ExecPay. In other words, Higgins earned more than 86.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,813 out of 13,090 | 86th |
Division Manufacturing | 698 out of 5,621 | 88th |
Major group Chemicals And Allied Products | 250 out of 2,254 | 89th |
Industry group Drugs | 209 out of 1,954 | 89th |
Industry Pharmaceutical Preparations | 148 out of 1,459 | 90th |
Source: SEC filing on April 22, 2022.
Higgins' colleagues
We found three more compensation records of executives who worked with John L. Higgins at Ligand Pharmaceuticals in 2020.